Yazar "Izquierdo, Guillermo" için listeleme
-
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Lorscheider, Johannes; Jokubaitis, Vilija G.; Spelman, Tim; Izquierdo, Guillermo; Lugaresi, Alessandra; Havrdova, Eva; Granella, Franco (Lippincott Williams & Wilkins, 2017)Objective: To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS). Methods: Using MSBase, an international cohort study, we previously ... -
Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis
Hughes, Jordana; Jokubaitis, Vilija; Lugaresi, Alessandra; Hupperts, Raymond; Izquierdo, Guillermo; Prat, Alexandre; Spitaleri, Daniele (Amer Medical Assoc, 2018)IMPORTANCE The role of inflammatory disease activity as a determinant of disability in progressive-onset multiple sclerosis (MS) remains contested. OBJECTIVE To examine the association of superimposed relapses in ... -
Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis
Brown, J. William L.; Coles, Alasdair; Horakova, Dana; Havrdova, Eva; Izquierdo, Guillermo; Prat, Alexandre; Pucci, Eugenio (Amer Medical Assoc, 2019)IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressiveMS. The association between ... -
A comparative effectiveness analysis applying a 3-way propensity score matching to real-world data from the MSBase registry in preparation for a cost-effectiveness model: patients switching within first-line agents or to either natalizumab or fingolimod in active relapsing-remitting multiple sclerosis
Spelman, Timothy; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Lugaresi, Alessandra; Izquierdo, Guillermo; Butzkueven, Helmut (Lippincott Williams & Wilkins, 2018)… -
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Kalincik, Tomas; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Prat, Alexandre; Girard, Marc; Turkoglu, Recai (Bmj Publishing Group, 2019)Objective Oral immunotherapies have become a standard treatment in relapsing-remitting multiple sclerosis. Direct comparison of their effect on relapse and disability is needed. Methods We identified all patients with ... -
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Warrender-Sparkes, Matthew; Spelman, Tim; Izquierdo, Guillermo; Trojano, Maria; Lugaresi, Alessandra; Grand'Maison, Francois; Van Pesch, Vincent (Sage Publications Ltd, 2016)Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis ... -
Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study
Nguyen, Ai-Lan; Havrdova, Eva Kubala; Horakova, Dana; Izquierdo, Guillermo; Kalincik, Tomas; van der Walt, Anneke; Granella, Franco (Elsevier Sci Ltd, 2019)Background: Exposure to disease-modifying therapy (DMT) during early pregnancy in women with relapsing-remitting MS (RAMS) may be increasing. Objective: To retrospectively determine incidence of pregnancy, DMT exposure and ... -
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis
Signori, Alessio; Izquierdo, Guillermo; Lugaresi, Alessandra; Hupperts, Raymond; Grand'Maison, Francois; Sola, Patrizia; Slee, Mark (Sage Publications Ltd, 2018)Background: Several natural history studies on primary progressive multiple sclerosis (PPMS) patients detected a consistent heterogeneity in the rate of disability accumulation. Objectives: To identify subgroups of PPMS ... -
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy
Kister, Ilya; Spelman, Tim; Patti, Francesco; Duquette, Pierre; Trojano, Maria; Izquierdo, Guillermo; Butzkueven, Helmut (Elsevier Science Bv, 2018)Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large global observational registry, affords a unique opportunity to investigate predictors of 'post-DMT' relapses and confirmed ... -
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice
Spelman, Tim; Meyniel, Claire; Ignacio Rojas, Juan; Lugaresi, Alessandra; Izquierdo, Guillermo; Grand'Maison, Francois; Kalincik, Tomas (Sage Publications Ltd, 2017)Background: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk of early second attack and could benefit the most from early disease-modifying drugs (DMDs). ...
